151 related articles for article (PubMed ID: 24212482)
1. ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia.
Menezes J; Salgado RN; Acquadro F; Gómez-López G; Carralero MC; Barroso A; Mercadillo F; Espinosa-Hevia L; Talavera-Casañas JG; Pisano DG; Alvarez S; Cigudosa JC
Blood Cancer J; 2013 Nov; 3(11):e157. PubMed ID: 24212482
[No Abstract] [Full Text] [Related]
2. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.
Bidikian A; Kantarjian H; Jabbour E; Short NJ; Patel K; Ravandi F; Sasaki K; Issa GC
Blood Cancer J; 2022 Oct; 12(10):144. PubMed ID: 36307398
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia.
Peller S; Yona R; Kopilova Y; Prokocimer M; Goldfinger N; Uysal A; Karabulut HG; Tukun A; Bokesoy I; Tuncman G; Rotter V
Genes Chromosomes Cancer; 1998 Jan; 21(1):2-7. PubMed ID: 9443036
[TBL] [Abstract][Full Text] [Related]
4. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
5. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
6. A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.
Imataki O; Ishida T; Kubo H; Uemura M; Nanya Y; Kawakami K; Ogawa S; Kadowaki N
Case Rep Oncol; 2020; 13(1):449-455. PubMed ID: 32399015
[TBL] [Abstract][Full Text] [Related]
7. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia.
Watzinger F; Gaiger A; Karlic H; Becher R; Pillwein K; Lion T
Cancer Res; 1994 Jul; 54(14):3934-8. PubMed ID: 8033117
[TBL] [Abstract][Full Text] [Related]
8. Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.
Kazemi-Sefat GE; Keramatipour M; Vaezi M; Razavi SM; Kavousi K; Talebi A; Rostami S; Yaghmaie M; Chahardouli B; Talebi S; Mousavizadeh K
Sci Rep; 2022 Jul; 12(1):12816. PubMed ID: 35896598
[TBL] [Abstract][Full Text] [Related]
9. Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation-an uncommon presentation in adults.
Krishnan S; Sabai K; Chuah C; Tan SY
Curr Oncol; 2014 Feb; 21(1):e147-50. PubMed ID: 24523612
[TBL] [Abstract][Full Text] [Related]
10. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
11. Genetic landscape of chronic myeloid leukemia.
Ochi Y
Int J Hematol; 2023 Jan; 117(1):30-36. PubMed ID: 36477676
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
Ahuja H; Bar-Eli M; Arlin Z; Advani S; Allen SL; Goldman J; Snyder D; Foti A; Cline M
J Clin Invest; 1991 Jun; 87(6):2042-7. PubMed ID: 2040694
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of clonal evolution in chronic myeloid leukemia].
Ochi Y
Rinsho Ketsueki; 2023; 64(5):369-375. PubMed ID: 37271527
[TBL] [Abstract][Full Text] [Related]
14.
Magistroni V; Mauri M; D'Aliberti D; Mezzatesta C; Crespiatico I; Nava M; Fontana D; Sharma N; Parker W; Schreiber A; Yeung D; Pirola A; Readelli S; Massimino L; Wang P; Khandelwal P; Citterio S; Viltadi M; Bombelli S; Rigolio R; Perego R; Boultwood J; Morotti A; Saglio G; Kim DW; Branford S; Gambacorti-Passerini C; Piazza R
Haematologica; 2019 Sep; 104(9):1789-1797. PubMed ID: 30819912
[TBL] [Abstract][Full Text] [Related]
15. Adenosine deaminase and ecto-5'-nucleotidase activities in various leukemias with special reference to blast crisis: significance of ecto-5'-nucleotidase in lymphoid blast crisis of chronic myeloid leukemia.
Koya M; Kanoh T; Sawada H; Uchino H; Ueda K
Blood; 1981 Dec; 58(6):1107-11. PubMed ID: 6272902
[TBL] [Abstract][Full Text] [Related]
16. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.
Makishima H; Jankowska AM; McDevitt MA; O'Keefe C; Dujardin S; Cazzolli H; Przychodzen B; Prince C; Nicoll J; Siddaiah H; Shaik M; Szpurka H; Hsi E; Advani A; Paquette R; Maciejewski JP
Blood; 2011 May; 117(21):e198-206. PubMed ID: 21346257
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia extramedullary blast crisis presenting as central nervous system leukemia: A case report.
Jin M; Xuan C; Gao J; Han R; Xu S; Wang L; Wang Y; Shi K; Rauniyar S; An Q
Medicine (Baltimore); 2018 Nov; 97(45):e13131. PubMed ID: 30407337
[TBL] [Abstract][Full Text] [Related]
18. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
[TBL] [Abstract][Full Text] [Related]
20. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
